A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study

We examined the neuro/axono-protective potential of a novel poly (ADP-ribose) polymerase (PARP) inhibitor L-2286 in a rat impact acceleration brain injury model. Male Wistar rats (n = 70) weighing 300–350 grams were used to determine the most effective intracerebroventricular (i.c.v.) dose of L-2286...

Descripción completa

Detalles Bibliográficos
Autores principales: Kövesdi, Erzsébet, Bukovics, Péter, Besson, Valérie, Nyirádi, József, Lückl, János, Pál, József, Sümegi, Balázs, Dóczi, Tamás, Hernádi, István, Büki, András
Formato: Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871115/
https://www.ncbi.nlm.nih.gov/pubmed/20480019
http://dx.doi.org/10.3390/ijms11041253
_version_ 1782181147011186688
author Kövesdi, Erzsébet
Bukovics, Péter
Besson, Valérie
Nyirádi, József
Lückl, János
Pál, József
Sümegi, Balázs
Dóczi, Tamás
Hernádi, István
Büki, András
author_facet Kövesdi, Erzsébet
Bukovics, Péter
Besson, Valérie
Nyirádi, József
Lückl, János
Pál, József
Sümegi, Balázs
Dóczi, Tamás
Hernádi, István
Büki, András
author_sort Kövesdi, Erzsébet
collection PubMed
description We examined the neuro/axono-protective potential of a novel poly (ADP-ribose) polymerase (PARP) inhibitor L-2286 in a rat impact acceleration brain injury model. Male Wistar rats (n = 70) weighing 300–350 grams were used to determine the most effective intracerebroventricular (i.c.v.) dose of L-2286 administered 30 min after injury, and to test the neuroprotective effect at two time points (immediately, and 30 min after injury). The neuroprotective effect of L-2286 was tested using immunohistochemical (amyloid precursor protein and mid-sized mouse anti-neurofilament clone RMO-14.9 antibody) and behavioral tests (beam-balance, open-field and elevated plus maze). At both time-points, a 100 μg/rat dose of i.c.v. L-2286 significantly (p < 0.05) reduced the density of damaged axons in the corticospinal tract and medial longitudinal fascicle compared to controls. In the behavioral tests, treatment 30 min post-injury improved motor function, while the level of anxiety was reduced in both treatment protocols.
format Text
id pubmed-2871115
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-28711152010-05-17 A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study Kövesdi, Erzsébet Bukovics, Péter Besson, Valérie Nyirádi, József Lückl, János Pál, József Sümegi, Balázs Dóczi, Tamás Hernádi, István Büki, András Int J Mol Sci Article We examined the neuro/axono-protective potential of a novel poly (ADP-ribose) polymerase (PARP) inhibitor L-2286 in a rat impact acceleration brain injury model. Male Wistar rats (n = 70) weighing 300–350 grams were used to determine the most effective intracerebroventricular (i.c.v.) dose of L-2286 administered 30 min after injury, and to test the neuroprotective effect at two time points (immediately, and 30 min after injury). The neuroprotective effect of L-2286 was tested using immunohistochemical (amyloid precursor protein and mid-sized mouse anti-neurofilament clone RMO-14.9 antibody) and behavioral tests (beam-balance, open-field and elevated plus maze). At both time-points, a 100 μg/rat dose of i.c.v. L-2286 significantly (p < 0.05) reduced the density of damaged axons in the corticospinal tract and medial longitudinal fascicle compared to controls. In the behavioral tests, treatment 30 min post-injury improved motor function, while the level of anxiety was reduced in both treatment protocols. Molecular Diversity Preservation International (MDPI) 2010-03-26 /pmc/articles/PMC2871115/ /pubmed/20480019 http://dx.doi.org/10.3390/ijms11041253 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Kövesdi, Erzsébet
Bukovics, Péter
Besson, Valérie
Nyirádi, József
Lückl, János
Pál, József
Sümegi, Balázs
Dóczi, Tamás
Hernádi, István
Büki, András
A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study
title A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study
title_full A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study
title_fullStr A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study
title_full_unstemmed A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study
title_short A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study
title_sort novel parp inhibitor l-2286 in a rat model of impact acceleration head injury: an immunohistochemical and behavioral study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871115/
https://www.ncbi.nlm.nih.gov/pubmed/20480019
http://dx.doi.org/10.3390/ijms11041253
work_keys_str_mv AT kovesdierzsebet anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT bukovicspeter anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT bessonvalerie anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT nyiradijozsef anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT luckljanos anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT paljozsef anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT sumegibalazs anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT doczitamas anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT hernadiistvan anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT bukiandras anovelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT kovesdierzsebet novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT bukovicspeter novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT bessonvalerie novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT nyiradijozsef novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT luckljanos novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT paljozsef novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT sumegibalazs novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT doczitamas novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT hernadiistvan novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy
AT bukiandras novelparpinhibitorl2286inaratmodelofimpactaccelerationheadinjuryanimmunohistochemicalandbehavioralstudy

Ejemplares similares